ReviewFrontiers in immunology2018
Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Assessing Immunization Coverage and the Negative Impact of Local Vaccine Production Cessation in Ecuador.Vaccines · 2025Article
- Securing the Future: Strategies for Global Polio Vaccine Security Amid Eradication Efforts.Vaccines · 2024Article
- Barriers to child vaccination: The role of international sanctions.SSM - population health · 2024Article
- Suitability of paediatric legislation beyond the USA and Europe: a qualitative study on access to paediatric medicines.BMJ public health · 2024Article
- Voluntariness or legal obligation? An ethical analysis of two instruments for fairer global access to COVID-19 vaccines.Frontiers in public health · 2023Article
- Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries.PLOS global public health · 2023Article
- Current GMP standards for the production of vaccines and antibodies: An overview.Frontiers in public health · 2022Review
- Strengthening Africa's capacity for vaccine research: Needs and challenges.Health promotion perspectives · 2022Review
- Review
- The Importance of Nanocarrier Design and Composition for an Efficient Nanoparticle-Mediated Transdermal Vaccination.Vaccines · 2021Review
- Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA.Molecular therapy. Nucleic acids · 2021Article
- Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?Frontiers in immunology · 2020Article
- Induction of Trained Immunity by Recombinant Vaccines.Frontiers in immunology · 2020Review
- BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design.Frontiers in immunology · 2019Review
- Insights on the crosstalk between dendritic cells and helper T cells in novel genetic etiology for mendelian susceptible mycobacterial disease.Cellular & molecular immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines have significantly reduced the detrimental effects of numerous human infectious diseases worldwide, helped to reduce drastically child mortality rates and even achieved eradication of major pathogens, such as smallpox. These achievements have been possible due to a dedicated effort for vaccine research and development, as well as an effective transfer of these vaccines to public health care systems globally. Either public or private institutions have committed to developing and manufacturing vaccines for local or international population supply. However, current vaccine manufacturers worldwide might not be able to guarantee sufficient vaccine supplies for all nations when epidemics or pandemics events could take place. Currently, different countries produce their own vaccine supplies under Good Manufacturing Practices, which include the USA, Canada, China, India, some nations in Europe and South America, such as Germany, the Netherlands, Italy, France, Argentina, and Brazil, respectively. Here, we discuss some of the vaccine programs and manufacturing capacities, comparing the current models of vaccine management between industrialized and developing countries. Because local vaccine production undoubtedly provides significant benefits for the respective population, the manufacture capacity of these prophylactic products should be included in every country as a matter of national safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.